Manchester-based CareLoop Health is reporting strong early traction following a £1.8m funding round from NPIF II – PXN Equity Finance, the GMC Life Sciences Fund by PXN Ventures, Verge HealthTech Fund and SFC Capital, supporting the business to scale its technology and expand clinical adoption across the UK and internationally.

Launched in 2021, Careloop Health is a University of Manchester spinout focused on transforming care in  severe mental illness, including schizophrenia and psychosis. Built on more than a decade of research and clinical trials prior to spinout, the CareLoop digital platform integrates into existing care pathways, enabling clinicians to remotely monitor patients while using algorithm-driven insights to predict and prevent relapses.

Since securing the investment in 2025, CareLoop Health has grown its team from two to ten employees, strengthening its clinical, technical and commercial capabilities as it moves towards wider adoption. The business has also secured an SBRI Healthcare grant along with funding from NHS England, enabling pilot programmes across five NHS trusts, while building a strong commercial pipeline as it looks to convert pilots into long-term contracts. The company’s growth reflects increasing momentum across the UK’s digital health and life sciences sectors, both identified as priority areas in the UK’s Modern Industrial Strategy.

Alongside its UK growth, CareLoop Health has begun expanding internationally, with two sites in the United States. The company has also been accepted into the NHS Innovation Accelerator, with COO Dr Pauline Whelan awarded a fellowship.